Study of KITE-363 or KITE-753 in Participants With Relapsed and/or Refractory B-cell Lymphoma
The goal of this clinical study is to learn more about the safety and dosing of the study drugs, KITE-363 and KITE-753, in participants with relapsed and/or refractory B-cell lymphoma.
Relapsed and/or Refractory B-cell Lymphoma
DRUG: Cyclophosphamide|DRUG: Fludarabine|BIOLOGICAL: KITE-363|BIOLOGICAL: KITE-753
Phase 1a: Percentage of Participants Experiencing Adverse Events Defined as Dose-limiting Toxicities (DLTs) After the Infusion of KITE-363 or KITE-753, DLTs are defined as the KITE-363-related or KITE-753-related events with onset within the first 28 days after the infusion of KITE-363 or KITE-753 respectively., Up to 28 days|Phase 1b: Objective Response Rate (ORR) for KITE-363 or KITE-753, ORR is defined as the percentage of participants with a complete response (CR) or a partial response (PR) by the International Working Group (IWG) Lugano Response Criteria for Malignant Lymphoma (Cheson 2014) as determined by investigator assessment., Up to 15 years
Percentage of Participants Experiencing Adverse Events (AEs) After the Infusion of KITE-363 or KITE-753, Up to 15 years|Percentage of Participants Experiencing Serious AEs (SAEs) After the Infusion of KITE-363 or KITE-753, Up to 15 years|Time To Next Treatment (TTNT) for KITE-363 or KITE-753, TTNT is defined as the time from KITE-363 or KITE-753 infusion to the next anticancer treatment (including stem cell transplantation \[SCT\]) or death from any cause, whichever occurs first., Up to 15 years|Complete Response (CR) Rate for KITE-363 or KITE-753, CR rate is defined as the incidence of a CR by the IWG Lugano Response Criteria for Malignant Lymphoma (Cheson 2014) as determined by investigator assessment., Up to 15 years|Duration of Response (DOR) for KITE-363 or KITE-753, DOR is defined only for participants who experience an objective response and is the time from the first objective response to disease progression per the IWG Lugano Classification or death due to any cause, whichever occurs first., Up to 15 years|Progression-Free Survival (PFS) for KITE-363 or KITE-753, PFS is defined as the time of KITE-363 or KITE-753 infusion to disease progression per IWG Lugano Response Criteria for Malignant Lymphoma (Cheson 2014) or death from any cause, whichever occurs first., Up to 15 years|Overall Survival (OS) for KITE-363 or KITE-753, OS is defined as the time from KITE-363 or KITE-753 infusion to death from any cause., Up to 15 years|Percentage of Participants who Develop Antibodies to KITE-363 or KITE-753 Chimeric Antigen Receptor (CAR) T Cells, Enrollment; up to 12 months|Levels of KITE-363 or KITE-753 CAR T Cells and Analytes (Including Cytokines) in the Blood, Up to 15 years|Peak Serum Levels of Key Analytes Homeostatic/Proliferative Cytokines: Interleukin (IL)-2, IL-7, and IL-15, Up to 3 months|Peak Serum Levels of Key Analytes Inflammatory/Immune Modulating Cytokines: IFN-γ, IL-6, IL-10, IL-17, IL-1RA, Granulocyte Macrophage-Colony Stimulating Factor (GM-CSF), and Tumor Necrosis Factor-Alpha (TNF-α), IFN-γ=Interferon-Gamma, IL-1 Receptor Antagonist=IL-1RA, Up to 3 months|Peak Serum Levels of Key Analytes Correlates of Acute Phase Response: C-Reactive Protein (CRP), Up to 3 months|Peak Serum Levels of Key Analytes Correlates of Acute Phase Response: Ferritin, Up to 3 months|Peak Serum Levels of Key Analytes Correlates of Acute Phase Response: Soluble IL-2 Receptor Alpha (Sil-2Rα), Up to 3 months|Peak Serum Levels of Key Analytes Chemokines: IL-8, C-X-C Motif Chemokine Ligand-10 (CXCL-10), and Monocyte Chemotactic Protein-1 (MCP-1), Up to 3 months|Peak Serum Levels of Key Analytes Immune-Effector Molecules: Perforin, Granzyme A, and Granzyme B, Up to 3 months
Eligible study participants who have received IP administration with either KITE-363 or KITE-753 will transition to a separate Long-term Follow-up study (Study KT-US-982-5968) to complete the remainder of the 15-year follow-up assessments.